HAW PAR CORPORATION LIMITED
80
NOTES TO THE FINANCIAL STATEMENTS
(CONTINUED)
For the financial year ended 31 December 2014
11. INVESTMENT IN SUBSIDIARIES
The Company
2014
$’000
2013
$’000
Equity investments at cost:
Unquoted, at written down cost
421,095
421,095
Allowance for impairment in value
(39,138)
(39,138)
Beginning and end of financial year
381,957
381,957
Details of significant subsidiaries are shown in Note 28.
12. INVESTMENT IN ASSOCIATED COMPANIES
The Company
2014
$’000
2013
$’000
Equity investment at cost
2,895
2,895
Set out below is the associated company of the Group as at 31 December 2014, which, in the opinion of the
Directors, is material to the Group. The associated company as listed below have share capital consisting solely of
ordinary shares, which are held directly by the Group.
Name of company
Country of incorporation Principal activities
% of ownership interest
Hua Han Bio-Pharmaceutical
Holdings Limited (“HHBP”)
Cayman Islands
Investment holding
14.4
HHBP is an investment holding company with subsidiaries which operate mainly in the People’s Republic of China
and its principal activity is that of manufacturing and sale of pharmaceutical products, trading of pharmaceutical
products and the research and development of pharmaceutical products.
HHBP is listed on the Hong Kong Stock Exchange. The fair value at the end of the reporting period is $229,893,000
(2013: $118,090,000). This is based on its quoted bid price as at 31 December 2014 and the exchange rate of
$1 = HK$5.92 (2013: $1 = HK$6.17).
The Group’s investment in HHBP has a carrying amount denominated in Hong Kong dollars with a Singapore-dollars
equivalent of $134,208,000 (2013: $115,845,000).
There are no contingent liabilities relating to the Group’s interest in the associated company.
